STOCK TITAN

Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. reported that director Thomas G. Wiggans received an automatic grant of a stock option covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The option expires on 2036-07-31 and, under the Non-Employee Director Compensation Policy, vests in full on the first anniversary of the 2026-07-31 grant date, subject to his continued board service.

Positive

  • None.

Negative

  • None.
Insider WIGGANS THOMAS G
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy F1 7,500 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy — 7,500 shares (Direct)
Footnotes (1)
  1. F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Option Shares Granted 7500.0000 shares Stock option covering Voting Common Stock granted to director on 2026-07-31
Exercise Price 0.6300 per share Conversion or exercise price of the stock option
Total Derivative Shares After Grant 7500.0000 shares Director’s total stock option holdings following this transaction
Option Expiration Date 2036-07-31 Expiration date of the granted stock option
Grant Date 2026-07-31 Date on which the non-employee director option was granted
Vesting Anniversary 1 year Option vests in full upon first anniversary of grant, subject to continued service
Non-Employee Director Compensation Policy financial
"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy"
stock option financial
"non-employee directors are automatically granted an option to purchase 7,500 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"which shall vest in full upon the first anniversary of the date of the grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price of 0.6300 per share for the stock option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did JSPR director Thomas G. Wiggans report?

Thomas G. Wiggans reported a grant of stock options for 7,500 shares of Jasper Therapeutics Voting Common Stock at an exercise price of $0.6300 per share, received as part of the Non-Employee Director Compensation Policy.

What are the key terms of Thomas G. Wiggans’ new JSPR stock options?

The option covers 7,500 shares of Voting Common Stock with a $0.6300 exercise price, was granted on 2026-07-31, becomes exercisable after one year of service, and expires on 2036-07-31.

How and when do Thomas G. Wiggans’ JSPR options vest?

The stock option vests in full on the first anniversary of the 2026-07-31 grant date, subject to Wiggans’ continued service as a non-employee director through that vesting date under the company’s policy.

Is the JSPR option grant to Thomas G. Wiggans a market purchase?

No. The transaction is a grant/award acquisition of a stock option with a $0.0000 transaction price per share, made automatically under Jasper Therapeutics’ Non-Employee Director Compensation Policy, not an open-market purchase.

How many derivative securities does Thomas G. Wiggans directly hold after this JSPR grant?

Following this reported transaction, Wiggans directly holds 7,500.0000 stock option derivatives related to Jasper Therapeutics’ Voting Common Stock, all from this single option grant reported in the Form 4 data.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
WIGGANS THOMAS G

(Last)(First)(Middle)
C/O JASPER THERAPEUTICS, INC.
2200 BRIDGE PKWY, SUITE #102

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy$0.6307/31/2026A7,50007/31/2027(1)07/31/2036(1)Voting Common Stock7,500$0.007,500D
Explanation of Responses:
1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
/s/ Herb Cross, as Attorney-in-Fact08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)